News

News

Aruvant to Participate in SVB Leerink’s Biopharma Private Company Connect December 15 to 17

NEW YORK and BASEL, Switzerland, Dec. 1, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment

0 comments

Aruvant Receives Orphan Designation from European Medicines Agency for Gene Therapy ARU-1801 for Sickle Cell Disease

NEW YORK and BASEL, Switzerland, Nov. 16, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment

0 comments

Aruvant Announces Updated Data to be Presented in Oral Presentation of ARU-1801 Data at the 62nd American Society of Hematology (ASH) Annual Meeting

–Ongoing manufacturing improvements shows enhanced efficacy of ARU-1801 for the treatment of sickle cell disease– New York, NY, Nov. 4, 2020 –Aruvant Sciences, a private

0 comments

Sickle Cell Disease Association of America and Aruvant Sciences Forge New Partnership to Educate Around Gene Therapy

Hanover, MD, and New York, NY, October 12, 2020 – The Sickle Cell Disease Association of America (SCDAA) and Aruvant Sciences are proud to announce

0 comments

Aruvant to Present at Investor and Scientific Conferences in October

NEW YORK and BASEL, Switzerland, Sept. 29, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment

0 comments

One-time Gene Therapy for Sickle Cell Disease

0 comments

Aruvant Appoints Dr. Palaniappan as Chief Technology Officer

Dr. Palaniappan joins Aruvant from Sarepta where he oversaw technical operations and was responsible for the development and registration of a portfolio of more than

0 comments

Aruvant Appoints Joseph McIntosh, M.D. as Chief Medical Officer

Dr. McIntosh joins to lead clinical development at Aruvant, including the program for ARU-1801, a one-time potentially curative gene therapy for patients with sickle cell

0 comments

Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease

ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a

0 comments

Aruvant Receives FDA Rare Pediatric Disease Designation for ARU-1801 for the Treatment of Sickle Cell Disease

ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a

0 comments